Provided by Tiger Fintech (Singapore) Pte. Ltd.

Organon & Co

15.73
+0.29001.88%
Post-market: 15.740.0100+0.06%18:48 EDT
Volume:3.99M
Turnover:63.05M
Market Cap:4.06B
PE:4.72
High:16.08
Open:15.36
Low:15.33
Close:15.44
Loading ...

Organon Finalizes Acquisition of Dermavant From Roivant

MT Newswires Live
·
28 Oct 2024

Organon completes acquisition of Dermavant

TIPRANKS
·
28 Oct 2024

Press Release: Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA(R) (tapinarof) Cream, 1%

Dow Jones
·
28 Oct 2024

Organon Completes Acquisition of Dermavant, Including Innovative Dermatologic Therapy, Vtama® (Tapinarof) Cream, 1%

THOMSON REUTERS
·
28 Oct 2024

Earnings Preview: Organon (OGN) Q3 Earnings Expected to Decline

Zacks
·
24 Oct 2024

Organon & Co trades in the red for seven straight sessions

seekingalpha
·
24 Oct 2024

With 80% institutional ownership, Organon & Co. (NYSE:OGN) is a favorite amongst the big guns

Simply Wall St.
·
20 Oct 2024

Organon (OGN) Loses -9.91% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks
·
09 Oct 2024

Organon Canada Promotes GeneviÈVe Gauthier as Executive Director, Corporate Affairs and Community Engagement and Appoints Jeffrey Malawski as Executive Director, Women's Health and Established Brands

THOMSON REUTERS
·
08 Oct 2024

Press Release: Organon Canada Promotes Geneviève Gauthier as Executive Director, Corporate Affairs and Community Engagement and Appoints Jeffrey Malawski as Executive Director, Women's Health and Established Brands

Dow Jones
·
08 Oct 2024

Organon's Propecia Medicine Under Review in Europe Over Risk of Suicidal Thoughts, Behaviors

MT Newswires Live
·
04 Oct 2024

Organon, Henlius Say Phase 3 Trial of Perjeta Biosimilar Meets Primary Endpoint

MT Newswires Live
·
30 Sep 2024

Organon & Co: Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (Pertuzumab) Biosimilar Candidate Hlx11

THOMSON REUTERS
·
30 Sep 2024

Are Options Traders Betting on a Big Move in Organon (OGN) Stock?

Zacks
·
25 Sep 2024

BRIEF-Organon & Co -On Sept 17, Co & Unit Entered Into Agreement And Plan Of Merger By Dermavant Sciences & Roivant Sciences

Reuters
·
24 Sep 2024

Organon & Co -Organon Has Agreed to Acquire Dermavant for Aggregate Consideration of up to Approximately $1.2 Billion

THOMSON REUTERS
·
24 Sep 2024